key: cord-0305521-htov9l03 authors: Behrens, C.; Samii-Moghadam, M.; Gasperazzo, T.; Gross, A. M.; Mitchell, J.; Lampe, J. B. title: COVID-19 vaccination, from first dose to booster: New insights into the frequency of most common systemic adverse events and possible booster nocebo effects based on a systematic review date: 2021-12-15 journal: nan DOI: 10.1101/2021.12.15.21267847 sha: cc3a42ccd758d843981ee6a30cf762b125014c1b doc_id: 305521 cord_uid: htov9l03 Background: Based on placebo data, it has been recently demonstrated that the frequencies of most common adverse events (AEs) of COVID-19 vaccination are overestimated due to negative expectation bias of vaccine recipients (nocebo effect). Since booster studies lack comparators, estimating the extent of the nocebo effect is difficult. We aimed to overcome this obstacle through a systematic comparison of most common AE frequencies across vaccine doses (first, second, booster), age groups, and vaccine vs. placebo arms. Methods: We systematically assessed systemic AEs in approved COVID-19 vaccines according to the PRISMA guidelines. All documents regarding COVID-19 vaccines with a booster dose authorized by the FDA (cutoff date 19 November 2021) were systematically searched on PubMed and the FDA website. Solicited systemic AEs from all documents supporting approval/authorization were collected. After standardization of doses and age groups, AE frequencies were compared between vaccine and placebo. Findings: Two trials were identified for BNT162b2 (n=21,785 participants), two for mRNA-1273 (n=22,324), and one for Ad26.COV2.S (n=4,085). Fever cases dropped to about half with the booster dose in all vaccines, whereas all other systemic AE frequencies were similar to the preceding dose. Almost no fever cases occurred with placebo (first/second dose); all other systemic AEs occurred at high frequencies. After subtracting placebo arm values from vaccine values, the frequencies for the various AEs were roughly comparable within each dose for each vaccine. Interpretation: Fever is the only solicited systemic AE that can be assessed objectively. It occurs about 50% less often with the booster than with the preceding dose. This may indirectly indicate a considerable overestimation of systemic AEs in the case of booster vaccinations and a pronounced nocebo effect. The nocebo effect appears to substantially contribute to the differences in the frequencies of the various systemic AEs. Instead of placebo AE data as reference parameter, we suggest fever as an objectively measurable value to estimate the extent of the nocebo effect in uncontrolled vaccination studies. To our knowledge, this is a new concept with 23 which evidence for the extent of a possible nocebo effect in COVID-19 booster vaccination can be provided. With 24 this approach we directly supplement information on the most recently reported nocebo effects in first, second and 25 booster vaccine doses. To the best of our knowledge, this is the first study to indirectly compare the solicited systemic AE frequencies of 27 approved COVID-19 vaccines across all doses, with easy-to-understand graphs and based on all approval-relevant 28 trials. This is astonishing, as in the context of a pandemic it is essential to communicate scientific data in a generally 29 understandable manner and according to the highest scientific standards. The graphs provided in this work could 30 serve as an example for such clear communication. Implications of all the available evidence 33 34 Using the example of systemic AEs, we were able to show that the frequency of AEs in COVID-19 booster 35 vaccination may be overestimated. Fever as an objective measure to estimate the nocebo effect could help to 36 optimize public awareness campaigns in the future. The graphic presentation of results facilitates a deeper 37 understanding of complex scientific data and provides new insights. It is therefore ideal for a highly dynamic 38 scientific field and may also be applied to other challenges in the COVID-19 pandemic and beyond. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Vaccination is an important tool to combat viral infections. In the case of COVID-19, the approved vaccines are well tolerated and most adverse events (AEs) are only mild 1 . Even more, the results of a recent study suggest that a substantial proportion of the AEs following COVID-19 vaccination may be due to a negative expectation bias of AEs. In this sense, the evaluation of AE frequencies after booster COVID-19 vaccines with a current Emergency Use 49 Authorization (EUA) in the USA (BNT162b2, mRNA-1273 and Ad26.COV2.S) is particularly challenging, since 50 the booster studies are not controlled and the reported AEs thus lack any reference parameter. We have recently published the results of the first approach that enables an indirect comparison of approved 52 COVID-19 vaccines using all available RCT data 3 . Here we apply the same approach to AEs occurring after the Study selection The PRISMA 2020 Statement 4 was adopted for study selection and data collection. A systematic search on (Table 3) . Only AEs occurring with at least two vaccines were analyzed. The data was standardized in order to 84 identify most comparable subgroups across the three vaccines. The data was analyzed and the results visualized 85 with the software TIBCO Spotfire (version 11.4.0). The selection process is depicted in Figure 1 . After exclusion of non-approved dosages and dosing schedules, ten 90 publications reporting on clinical trials were identified (Table 1) The data structure showed three trial phases (I-III) ( Table 1) , various numbers of subjects depending on trial phase 95 (Table 2) , and three distinct dose analysis sets (first dose vs. second dose vs. booster dose). Moreover, eleven age 96 ranges were identified across the three analyzed vaccines; a standardization step as shown in Table 3 allowed their 97 clustering into three age groups: Overall, middle-aged, and senior participants. The overall group would best 98 represent the general population; however, data was available in all studies only for the groups of middle-aged and 99 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.15.21267847 doi: medRxiv preprint senior participants. Therefore, for this assessment, only the middle-aged group was included, as it is believed to represent the general population better than the senior group (Table 4) . Accordingly, five publications were found suitable for safety analysis per administration dose (Table 2) , reporting data on five trials: One phase I-III study was assessed for BNT162b2 (reported in one original article and one FDA document), whereas for mRNA-1273 vaccine Ad26.COV2.S only requires a single initial dose, we compared the data for the first dose with that of the Table 1. Stepwise selection of publications (i.e. sources) containing relevant information to be included in the safety assessment of COVID-19 vaccines (first, second and booster dose) approved or authorized in the USA. Ten publications were initially identified and compiled in a SQL database. A) All ten identified publications containing relevant information (i.e. prospective data from clinical trials) about the safety of COVID-19 vaccines approved or authorized in the USA (first, second and booster dose). B) Standardization step to identify comparable age groups among all trials. C) Publications with comparable safety outcomes reported separately for the first, second and booster vaccine doses in middle-aged participants. ClinicalTrials Table 4 . Age groups reported in publications providing safety data for each vaccine. Please note that the overall group would best represent the general population; however, data was available in all studies only for the groups of middle-aged and senior participants. Therefore, for this assessment, only the middle-aged group was included, as it is believed to represent the general population better than the senior group. Age groups included in assessment BNT162b2 mRNA-1273 Ad26.COV2.S . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure 1. Flowchart showing the selection process for the data to be included in the present vaccine safety outcome assessment (as described in Table 1 ). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.15.21267847 doi: medRxiv preprint COVID-19 advice for the public: Getting vaccinated Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review An objective systematic comparison of the most common adverse events of COVID-19 vaccines The PRISMA 2020 statement: An updated guideline for reporting systematic reviews The how's and what's of vaccine reactogenicity COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates FDA Fact Sheet: Emergency Use Authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised version 19 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults An mRNA vaccine against SARS-CoV-2 -Preliminary report Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine FDA Fact Sheet: Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised version 20 FDA Fact Sheet: Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised version 20 Nocebo affects after COVID-19 vaccination Placebo and nocebo effects across symptoms: From pain to fatigue, dyspnea, nausea, and itch Nocebo phenomena in medicine: their relevance in everyday clinical practice